Featuring: Tristel Plc (TSTL), Inspiration Healthcare Group (IHC), Creo Medical Group (CREO), Abingdon Health (ABDX) and GENincode (GENI)
Date: 19 October 2023
For the first time, our in-person seminar will be available via live stream.
Remember, Stockopedia will be providing attendees with key facts and figures about the presenting companies. Plus, ShareSoc subscribing members can enjoy a special discount on Stockopedia subscription rates – see Member Offers for details.
Tristel Plc (TSTL): Tristel plc is a UK-based manufacturer of infection prevention products. The Company’s core business is the sale to hospitals of its Chlorine Dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand. Tristel’s powerful and fast acting disinfectant uses a proprietary formulation of Chlorine Dioxide and is used in nearly every NHS hospital to decontaminate medical devices or as a surface disinfectant, as well as across 30 plus countries worldwide.
Speakers: Paul Swinney (CEO) and Liz Dixon (CFO)
Inspiration Healthcare Group (IHC): Inspiration Healthcare is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.
The Company has key own-brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.
Speakers: Neil Campbell (CEO) and Alan Olby (CFO)
Creo Medical Group (CREO): Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency (“RF”) energy for precise localised cutting and focused high-frequency microwave (“MW”) energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group’s range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company’s technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
Speaker: Craig Gulliford (CEO)
Abingdon Health (ABDX): Abingdon Health is a leading lateral flow contract development and manufacturing organisation (“CDMO”) offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing.
The Company’s CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in, allowing for rapid decision making, targeted intervention and supporting better outcomes.
Speakers: Chris Yates (CEO) and Melanie Ross (CFO)
GENincode (GENI): GENinCode plc is a UK-based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode’s CE marked in vitro diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.
Speakers: Matthew Walls (CEO) and Paul Foulger (CFO)
The seminar will consist of a 15-minute presentation, followed by a 15-minute Q&A session, for each company.
If you are already a member of ShareSoc you must log in prior to registering, then just click “REGISTER” below. If you are not a ShareSoc member, you will automatically be registered as a free, associate member by registering for this event
Click here for help on logging in.
Once you have registered you will receive an email notification, as well as reminders 1 day and 1 hour before the event starts.